Kairos Pharma, LTD. (KAPA) stock
KAPANYSEPharmaceutical PreparationsFiscal year ends December 31
$0.40−0.01 (-1.70%)
Close on Nov 17, 2026Market cap $1.49MP/E –Yield –
Kairos Pharma r&d expenses
Research and development expenses are spending on new products and technology.
Kairos Pharma's R&D Expenses for the twelve months ending Sep 30, 2026 was $2.73M, up 54.5% year over year. For fiscal 2025 it was $2.14M, up 415.7% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.14M | +415.7% |
| FY2024 | Dec 31, 2024 | $414.00K | +404.9% |
| FY2023 | Dec 31, 2023 | $82.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $892.00K | +46.7% |
| Q2 FY2026 | Jun 30, 2026 | $619.00K | +24.8% |
| Q1 FY2026 | Mar 31, 2026 | $684.00K | +38.7% |
| Q4 FY2025 | Dec 31, 2025 | $538.00K | +212.8% |
| Q3 FY2025 | Sep 30, 2025 | $608.00K | +4242.9% |
| Q2 FY2025 | Jun 30, 2025 | $496.00K | +687.3% |
| Q1 FY2025 | Mar 31, 2025 | $493.00K | +198.8% |
| Q4 FY2024 | Dec 31, 2024 | $172.00K | +2357.1% |
| Q3 FY2024 | Sep 30, 2024 | $14.00K | -57.6% |
| Q2 FY2024 | Jun 30, 2024 | $63.00K | – |
| Q1 FY2024 | Mar 31, 2024 | $165.00K | – |
| Q4 FY2023 | Dec 31, 2023 | $7.00K | – |
| Q3 FY2023 | Sep 30, 2023 | $33.00K | – |
See a number that looks wrong?